Loading...
Not a good buy right now for an impatient investor. RAND is still in a broader bearish trend (down-trend structure via moving averages) and there are no Intellectia entry signals today to justify an immediate buy. While insider buying and a slightly improving MACD suggest a possible stabilization, the latest quarter (2025/Q3) shows sharply worsening losses, and there are no near-term news catalysts to drive a quick upside move. I would wait rather than buy now.
Trend/structure: Bearish. The moving averages are stacked bearishly (SMA_200 > SMA_20 > SMA_5), which typically signals the primary trend remains down. Momentum: Improving but not decisive. MACD histogram is positive (0.0838) and expanding, suggesting downside momentum is easing and a rebound attempt is possible. RSI(6) ~47.8 is neutral, not indicating an oversold bounce signal. Key levels: Price 11.02 is slightly below/near S1 (11.073), with next support at S2 (10.794). Upside resistance is the pivot (11.526) then R1 (11.979). A clean reclaim of 11.53 would be the first technical improvement; failing that increases odds of a dip toward 10.79. Pattern-based forward view (provided): Near-term expected move is small (next day -0.66% probability skew), with modest positive bias over 1 week (+0.62%) and 1 month (+4.7%), but this is not strong enough to override the bearish trend.
Intellectia Proprietary Trading Signals
Insiders are buying (buying amount up ~356% over the last month), which can be a confidence signal.
MACD has turned positive and is expanding, hinting at a potential short-term stabilization or bounce from support.
Price is near a defined support zone (around 11.07 / 10.79), which can attract dip buyers if it holds.
Primary trend remains bearish (SMA_200 > SMA_20 > SMA_5), so rallies can fail under resistance (11.53–11.98).
No news in the past week, implying no clear event-driven catalyst for a fast move.
Hedge fund stance is neutral with no notable accumulation trend over the last quarter.
If 11.07 fails to hold, next support is ~10.79, creating immediate downside risk.
Latest quarter: 2025/Q3. Results deteriorated materially YoY: Revenue fell to -1,644,150 (-143.46% YoY), Net Income fell to -2,231,194 (-184.63% YoY), and EPS dropped to -0.75 (-173.53% YoY). Overall, the quarter reflects worsening profitability and weak growth momentum, which reduces the likelihood of a quick, sentiment-driven rerating without a catalyst.
Only one rating item is provided, and it appears to reference a different company (Randstad) rather than Rand Capital Corp (RAND), so it is not reliable for RAND-specific sentiment. As a result, there is no clear, actionable Wall Street pro/con picture from the supplied analyst data. Based on the rest of the dataset, the most supportive 'pro' is insider buying; the main 'con' is the weak, deteriorating 2025/Q3 performance combined with a bearish technical trend.
Politicians/influential figures: No recent congress trading data available in the last 90 days.